Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ARG1 | P05089 | 5/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806367 | 0.75 | SLC1A2 (0.59) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL2806369 | 0.75 | SLC1A2 (0.59) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL11511873 | 0.75 | SLC1A2 (0.59) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL11511876 | 0.75 | SLC1A2 (0.59) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL19640960 | 0.72 | — | — | |
| SCHEMBL28906785 | 0.72 | SLC1A2 (0.52) | SLC1A2MEN1BLMKMT2A | |
| SCHEMBL7322888 | 0.70 | SLC1A2 (0.48) | SLC1A2MEN1BLMKMT2AARG1 | |
| Hydrochloric Acid SCHEMBL31389450 | 0.68 | MEN1 (0.53) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL17043094 | 0.65 | SLC1A2 (0.31) | SLC1A2 | |
| SCHEMBL4332743 | 0.65 | SLC1A2 (0.43) | SLC1A2MEN1BLMKMT2AARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569690-B2 | Process for producing oxycarbonyl-substituted piperazine derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20060161003-A1 | Process for producing oxycarbonyl-substituted piperazine derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1548010-A1 | PROCESS FOR PRODUCING OXYCARBONYL-SUBSTITUTED PIPERAZINE DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060161003-A1 | Process for producing oxycarbonyl-substituted piperazine derivative | DHPS, AQP4, OGFOD1 | SLC1A2 4225/4885MEN1 4853/4885BLM 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.